28 reports

Bile acid sequestrates lead to side effects related to the gastrointestinal tract.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • WELCHOL SWOT ANALYSIS, 2015

PLOS ONE; ##(##): ##-##.

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Category Increase in Incidence of High Cholesterol Increase in Prevalence of Chronic Diseases Changes in Cholesterol Treatment Guidelines Increase in Aging Population Expected Entry of Cost- Effective OTC Versions ## ## ## ## ## Hospitals Low Low

  • Cholesterol
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

S##. and Rehabilitation; ##(##): ##-##.

  • Cholesterol
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • DYSLIPIDEMIA - PIPELINE BY SJT MOLECULAR RESEARCH SL, H1 2018

Dyslipidemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation...

  • Cardiovascular Disease
  • Cholesterol
  • Chronic Disease
  • Pharmaceutical
  • Amarin Corporation plc
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • DYSLIPIDEMIA - PIPELINE BY SJT MOLECULAR RESEARCH SL, H2 2018

Dyslipidemia - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation...

  • Cholesterol
  • Chronic Disease
  • United States
  • Product Initiative
  • Amarin Corporation plc
  • HS-25 - Drug Profile

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The majority of AEs were gastrointestinal.

  • Cholesterol
  • Therapy
  • United States
  • Company
  • Gemphire Therapeutics Inc.
  • Phase II - Trial Details
  • R&D Progress Research and Development Brief

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Cholesterol
  • South Korea
  • United States
  • World
  • Product Initiative

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • South Korea
  • Turkey
  • World
  • Product Initiative

SYMPTOMS INCLUDE GASTROINTESTINAL PAIN, DIFFICULTY BREATHING, MEMORY LOSS, DEMENTIA, XANTHELASMAS AND CORNEAL ARCUS.

  • Cholesterol
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

ATP Binding Cassette Sub Family A Member ## (ATP Binding Cassette Transporter ## or ABC ## or ATP Binding Cassette ## or Cholesterol Efflux Regulatory Protein or ABCA##) pipeline Target constitutes close to ## molecules.

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • Clinical Trial profile. 479 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

Similarly, the Universities' portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • LipimetiX Development LLC

Growth in molecular biology lines was driven by the ongoing fast-paced development of FilmArray®, and in particular the Gastrointestinal and Meningitis/ Encephalitis panels.

  • Cholesterol
  • Clinical Trial
  • Diagnostics
  • United States
  • GlobalData's company
  • Clinical Trial profile. 1413 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • World

ATP Binding Cassette Sub Family A Member ## (ATP Binding Cassette Transporter ## or ABC ## or ATP Binding Cassette ## or Cholesterol Efflux Regulatory Protein or ABCA##) pipeline Target constitutes close to ## molecules.

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • MIXED DYSLIPIDEMIA - PIPELINE BY HANMI PHARMACEUTICALS, CO. LTD., H1 2016
  • MIXED DYSLIPIDEMIA - PIPELINE BY PFIZER INC., H1 2016

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.

JD-## acts as a cannabinoid receptor type ## (CB##) antagonist.

  • Analgesic
  • Cholesterol
  • Obesity
  • Research And Development
  • Jenrin Discovery, Inc.

Previously, the Company had expected to initiate a Phase ## clinical trial.

  • Cholesterol
  • United States
  • Company Operations
  • Product Initiative
  • Vitae Pharmaceuticals, Inc.

GLP-## and GIP hormones are involved in the physiologic regulation of glucose homeostasis.

  • Cholesterol
  • Therapy
  • World
  • Company Operations
  • Kowa Co., Ltd.

Mild-to-moderate gastrointestinal adverse events have been the most commonly reported side effect in this trial.

  • Cholesterol
  • United States
  • Company Operations
  • Product Initiative
  • Aegerion Pharmaceuticals, Inc.

The predominant incidence was gastrointestinal related, with no difference between CaPre and placebo.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Product Initiative
  • Acasti Pharma Inc.